Published in Eur Radiol on July 13, 2004
Superparamagnetic iron oxide nanoparticles: diagnostic magnetic resonance imaging and potential therapeutic applications in neurooncology and central nervous system inflammatory pathologies, a review. J Cereb Blood Flow Metab (2009) 2.43
Ultrasmall superparamagnetic iron oxides (USPIOs): a future alternative magnetic resonance (MR) contrast agent for patients at risk for nephrogenic systemic fibrosis (NSF)? Kidney Int (2008) 2.09
Perturbational profiling of nanomaterial biologic activity. Proc Natl Acad Sci U S A (2008) 2.04
Size, charge and concentration dependent uptake of iron oxide particles by non-phagocytic cells. Biomaterials (2008) 1.91
Molecular imaging with nanoparticles: giant roles for dwarf actors. Histochem Cell Biol (2008) 1.73
T1 and T2 relaxivity of intracellular and extracellular USPIO at 1.5T and 3T clinical MR scanning. Eur Radiol (2005) 1.69
In vivo tracking of genetically engineered, anti-HER2/neu directed natural killer cells to HER2/neu positive mammary tumors with magnetic resonance imaging. Eur Radiol (2004) 1.44
Nanotherapeutics for inhibition of atherogenesis and modulation of inflammation in atherosclerotic plaques. Cardiovasc Res (2015) 1.39
Cell labeling with the positive MR contrast agent Gadofluorine M. Eur Radiol (2007) 1.32
The influence of ferucarbotran on the chondrogenesis of human mesenchymal stem cells. Contrast Media Mol Imaging (2009) 1.24
Enhanced cellular uptake of aminosilane-coated superparamagnetic iron oxide nanoparticles in mammalian cell lines. Int J Nanomedicine (2012) 1.23
Optical imaging of experimental arthritis using allogeneic leukocytes labeled with a near-infrared fluorescent probe. Eur J Nucl Med Mol Imaging (2006) 1.21
Monocyte subset dynamics in human atherosclerosis can be profiled with magnetic nano-sensors. PLoS One (2009) 1.20
Relaxation effects of ferucarbotran-labeled mesenchymal stem cells at 1.5T and 3T: discrimination of viable from lysed cells. Magn Reson Med (2009) 1.17
Photothermal treatment of glioma; an in vitro study of macrophage-mediated delivery of gold nanoshells. J Neurooncol (2011) 1.13
In Vivo Cellular Imaging for Translational Medical Research. Curr Med Imaging Rev (2009) 1.12
NanoFerrite particle based radioimmunonanoparticles: binding affinity and in vivo pharmacokinetics. Bioconjug Chem (2008) 1.11
Labeling stem cells with ferumoxytol, an FDA-approved iron oxide nanoparticle. J Vis Exp (2011) 1.09
Fluorophore-conjugated iron oxide nanoparticle labeling and analysis of engrafting human hematopoietic stem cells. Stem Cells (2007) 1.04
Macrophages as cell-based delivery systems for nanoshells in photothermal therapy. Ann Biomed Eng (2011) 1.03
Magnetic resonance imaging of ferumoxide-labeled mesenchymal stem cells in cartilage defects: in vitro and in vivo investigations. Mol Imaging (2012) 0.97
MRI in rodent models of brain disorders. Neurotherapeutics (2011) 0.94
Different capacity of monocyte subsets to phagocytose iron-oxide nanoparticles. PLoS One (2011) 0.94
Recent advances in superparamagnetic iron oxide nanoparticles for cellular imaging and targeted therapy research. Curr Pharm Des (2013) 0.92
Determining the fate of seeded cells in venous tissue-engineered vascular grafts using serial MRI. FASEB J (2011) 0.92
In vivo delivery, pharmacokinetics, biodistribution and toxicity of iron oxide nanoparticles. Chem Soc Rev (2015) 0.92
Evaluation of tumoral enhancement by superparamagnetic iron oxide particles: comparative studies with ferumoxtran and anionic iron oxide nanoparticles. Eur Radiol (2005) 0.92
In vivo magnetic resonance imaging and optical imaging comparison of viable and nonviable mesenchymal stem cells with a bifunctional label. Mol Imaging (2010) 0.91
Characterization of carotid artery plaques with USPIO-enhanced MRI: assessment of inflammation and vascularity as in vivo imaging biomarkers for plaque vulnerability. Int J Cardiovasc Imaging (2010) 0.91
Accelerated stem cell labeling with ferucarbotran and protamine. Eur Radiol (2009) 0.90
Magnetic resonance imaging probes for labeling of chondrocyte cells. J Mater Sci Mater Med (2011) 0.89
Receptor-targeted iron oxide nanoparticles for molecular MR imaging of inflamed atherosclerotic plaques. Biomaterials (2011) 0.89
Molecular magnetic resonance imaging of brain-immune interactions. Front Cell Neurosci (2014) 0.88
Cell therapy in myocardial infarction: emphasis on the role of MRI. Eur Radiol (2007) 0.87
Detection of postoperative granulation tissue with an ICG-enhanced integrated OI-/X-ray System. J Transl Med (2008) 0.86
Quantitative effects of cell internalization of two types of ultrasmall superparamagnetic iron oxide nanoparticles at 4.7 T and 7 T. Eur Radiol (2009) 0.85
Hybrid magnetic nanostructures (MNS) for magnetic resonance imaging applications. Adv Drug Deliv Rev (2011) 0.85
Ferumoxtran-10-enhanced MR imaging of the bone marrow before and after conditioning therapy in patients with non-Hodgkin lymphomas. Eur Radiol (2005) 0.84
Increased nanoparticle-loaded exogenous macrophage migration into the brain following PDT-induced blood-brain barrier disruption. Lasers Surg Med (2013) 0.84
Magnetic resonance imaging of iron-oxide labeled SK-Mel 28 human melanoma cells in the chick embryo using a clinical whole body MRI scanner. MAGMA (2006) 0.83
Mechanism of cellular uptake and impact of ferucarbotran on macrophage physiology. PLoS One (2011) 0.83
Certain types of iron oxide nanoparticles are not suited to passively target inflammatory cells that infiltrate the brain in response to stroke. J Cereb Blood Flow Metab (2013) 0.83
Magnetic resonance imaging of monocytes labeled with ultrasmall superparamagnetic particles of iron oxide using magnetoelectroporation in an animal model of multiple sclerosis. Mol Imaging (2010) 0.83
Tracking cell fate with noninvasive imaging. J Am Coll Cardiol (2009) 0.83
A role of cellular glutathione in the differential effects of iron oxide nanoparticles on antigen-specific T cell cytokine expression. Int J Nanomedicine (2011) 0.81
Pace of macrophage recruitment during different stages of soft tissue infection: semi-quantitative evaluation by in vivo magnetic resonance imaging. Eur Radiol (2008) 0.80
Visualization of antigen-specific human cytotoxic T lymphocytes labeled with superparamagnetic iron-oxide particles. Eur Radiol (2008) 0.80
Application of magnetic field hyperthermia and superparamagnetic iron oxide nanoparticles to HIV-1-specific T-cell cytotoxicity. Int J Nanomedicine (2013) 0.79
Targeted transplantation of iron oxide-labeled, adipose-derived mesenchymal stem cells in promoting meniscus regeneration following a rabbit massive meniscal defect. Exp Ther Med (2015) 0.79
Highly sensitive magnetite nano clusters for MR cell imaging. Nanoscale Res Lett (2012) 0.78
Nanoclusters of iron oxide: effect of core composition on structure, biocompatibility, and cell labeling efficacy. Bioconjug Chem (2012) 0.78
Magnetic resonance imaging-guided adoptive cellular immunotherapy of central nervous system tumors with a T1 contrast agent. Magn Reson Med (2009) 0.78
Magnetic Nanoparticles: Material Engineering and Emerging Applications in Lithography and Biomedicine. J Mater Sci (2015) 0.78
Labeling human embryonic stem-cell-derived cardiomyocytes for tracking with MR imaging. Pediatr Radiol (2011) 0.77
Effect of concentration of SH U 555A labeled human melanoma cells on MR spin echo and gradient echo signal decay at 0.2, 1.5, and 3T. MAGMA (2006) 0.77
Fast low-angle positive contrast steady-state free precession imaging of USPIO-labeled macrophages: theory and in vitro experiment. Magn Reson Imaging (2009) 0.77
MR Imaging of Stem Cell Transplants in Arthritic Joints. J Stem Cell Res Ther (2014) 0.75
Evaluation of PEG-coated iron oxide nanoparticles as blood pool tracers for preclinical magnetic particle imaging. Nanoscale (2017) 0.75
Silica-coated upconversion lanthanide nanoparticles: The effect of crystal design on morphology, structure and optical properties. Beilstein J Nanotechnol (2015) 0.75
g-force induced giant efficiency of nanoparticles internalization into living cells. Sci Rep (2015) 0.75
Superparamagnetic iron oxide contrast agents: physicochemical characteristics and applications in MR imaging. Eur Radiol (2001) 4.84
Superparamagnetic iron oxide: pharmacokinetics and toxicity. AJR Am J Roentgenol (1989) 3.59
Ultrasmall superparamagnetic iron oxide: characterization of a new class of contrast agents for MR imaging. Radiology (1990) 3.50
Magnetic resonance imaging of atherosclerotic plaque with ultrasmall superparamagnetic particles of iron oxide in hyperlipidemic rabbits. Circulation (2001) 2.55
YOPRO-1 permits cytofluorometric analysis of programmed cell death (apoptosis) without interfering with cell viability. J Immunol Methods (1995) 2.25
Magnetically labeled cells can be detected by MR imaging. J Magn Reson Imaging (1997) 1.97
Application of the static dephasing regime theory to superparamagnetic iron-oxide loaded cells. Magn Reson Med (2002) 1.95
Targeting of hematopoietic progenitor cells with MR contrast agents. Radiology (2003) 1.72
Initial clinical experience with dextran-coated superparamagnetic iron oxide for detection of lymph node metastases in patients with head and neck cancer. Radiology (1994) 1.67
Imaging single mammalian cells with a 1.5 T clinical MRI scanner. Magn Reson Med (2003) 1.51
Surface properties of superparamagnetic iron oxide MR contrast agents: ferumoxides, ferumoxtran, ferumoxsil. Magn Reson Imaging (1995) 1.38
Superparamagnetic iron oxides as positive MR contrast agents: in vitro and in vivo evidence. Magn Reson Imaging (1993) 1.17
Phase I clinical evaluation of a new iron oxide MR contrast agent. J Magn Reson Imaging (1994) 1.15
Selective MR imaging of labeled human peripheral blood mononuclear cells by liposome mediated incorporation of dextran-magnetite particles. Magn Reson Med (1993) 1.11
In vitro characterization of two different ultrasmall iron oxide particles for magnetic resonance cell tracking. Invest Radiol (2002) 1.02
Comparison of two blood pool contrast agents for 0.5-T MR angiography: experimental study in rabbits. Radiology (2000) 1.01
Induction of mitochondrial manganese superoxide dismutase in macrophages by oxidized LDL: its relevance in atherosclerosis of humans and heritable hyperlipidemic rabbits. FASEB J (1997) 1.00
Ceramide induces aSMase expression: implications for oxLDL-induced apoptosis. FASEB J (2001) 0.96
Method for intracellular magnetic labeling of human mononuclear cells using approved iron contrast agents. Magn Reson Imaging (1999) 0.95
Iron-oxide-enhanced MR imaging of bone marrow in patients with non-Hodgkin's lymphoma: differentiation between tumor infiltration and hypercellular bone marrow. Eur Radiol (2002) 0.92
Dose and scanning delay using USPIO for central nervous system macrophage imaging. MAGMA (1999) 0.91
Extra- and intracellular accumulation of ultrasmall superparamagnetic iron oxides (USPIO) in experimentally induced abscesses of the peripheral soft tissues and their effects on magnetic resonance imaging. Magn Reson Imaging (1999) 0.81
Mutations in dynein link motor neuron degeneration to defects in retrograde transport. Science (2003) 4.40
Monocytes, neutrophils, and platelets cooperate to initiate and propagate venous thrombosis in mice in vivo. J Exp Med (2012) 3.63
First clinical experience with integrated whole-body PET/MR: comparison to PET/CT in patients with oncologic diagnoses. J Nucl Med (2012) 2.76
SPECT/CT. J Nucl Med (2008) 2.34
Migration of iron oxide-labeled human hematopoietic progenitor cells in a mouse model: in vivo monitoring with 1.5-T MR imaging equipment. Radiology (2005) 2.25
Characterization of focal liver lesions by ADC measurements using a respiratory triggered diffusion-weighted single-shot echo-planar MR imaging technique. Eur Radiol (2007) 2.07
Platelets secrete stromal cell-derived factor 1alpha and recruit bone marrow-derived progenitor cells to arterial thrombi in vivo. J Exp Med (2006) 1.98
Reliability of MR imaging-based virtual cystoscopy in the diagnosis of cancer of the urinary bladder. AJR Am J Roentgenol (2002) 1.88
Aurora kinases A and B are up-regulated by Myc and are essential for maintenance of the malignant state. Blood (2010) 1.76
Targeting of hematopoietic progenitor cells with MR contrast agents. Radiology (2003) 1.72
Iron administration before stem cell harvest enables MR imaging tracking after transplantation. Radiology (2013) 1.70
T1 and T2 relaxivity of intracellular and extracellular USPIO at 1.5T and 3T clinical MR scanning. Eur Radiol (2005) 1.69
Protein kinase c-β-dependent activation of NF-κB in stromal cells is indispensable for the survival of chronic lymphocytic leukemia B cells in vivo. Cancer Cell (2013) 1.68
Initial performance characterization of a clinical noise-suppressing reconstruction algorithm for MDCT. AJR Am J Roentgenol (2011) 1.62
Inadequacy of manual measurements compared to automated CT volumetry in assessment of treatment response of pulmonary metastases using RECIST criteria. Eur Radiol (2005) 1.55
Value of a Dixon-based MR/PET attenuation correction sequence for the localization and evaluation of PET-positive lesions. Eur J Nucl Med Mol Imaging (2011) 1.54
Cell tracking with optical imaging. Eur Radiol (2008) 1.47
Differentiation of normal thymus from anterior mediastinal lymphoma and lymphoma recurrence at pediatric PET/CT. Radiology (2011) 1.46
C/EBPdelta is a crucial regulator of pro-apoptotic gene expression during mammary gland involution. Development (2005) 1.45
In vivo tracking of genetically engineered, anti-HER2/neu directed natural killer cells to HER2/neu positive mammary tumors with magnetic resonance imaging. Eur Radiol (2004) 1.44
Cell tracking with gadophrin-2: a bifunctional contrast agent for MR imaging, optical imaging, and fluorescence microscopy. Eur J Nucl Med Mol Imaging (2004) 1.43
Value of diffusion-weighted MR imaging in the differentiation between benign and malignant cervical lymph nodes. Eur J Radiol (2008) 1.42
Asparagine synthetase as a causal, predictive biomarker for L-asparaginase activity in ovarian cancer cells. Mol Cancer Ther (2006) 1.41
Platelets contribute to postnatal occlusion of the ductus arteriosus. Nat Med (2009) 1.41
Therapeutic implications for the induced levels of Chk1 in Myc-expressing cancer cells. Clin Cancer Res (2011) 1.41
Patellar articular cartilage lesions: in vitro MR imaging evaluation after placement in gadopentetate dimeglumine solution. Radiology (2004) 1.41
Anterior shoulder instability: accuracy of MR arthrography in the classification of anteroinferior labroligamentous injuries. Radiology (2005) 1.34
Cell labeling with the positive MR contrast agent Gadofluorine M. Eur Radiol (2007) 1.32
Platelet adhesion via glycoprotein IIb integrin is critical for atheroprogression and focal cerebral ischemia: an in vivo study in mice lacking glycoprotein IIb. Circulation (2005) 1.25
The influence of ferucarbotran on the chondrogenesis of human mesenchymal stem cells. Contrast Media Mol Imaging (2009) 1.24
Computer-assisted detection of pulmonary nodules: performance evaluation of an expert knowledge-based detection system in consensus reading with experienced and inexperienced chest radiologists. Eur Radiol (2004) 1.23
Preliminary results for characterization of pelvic lymph nodes in patients with prostate cancer by diffusion-weighted MR-imaging. Invest Radiol (2010) 1.22
Comparison of integrated whole-body [11C]choline PET/MR with PET/CT in patients with prostate cancer. Eur J Nucl Med Mol Imaging (2013) 1.21
Optical imaging of experimental arthritis using allogeneic leukocytes labeled with a near-infrared fluorescent probe. Eur J Nucl Med Mol Imaging (2006) 1.21
Protein-water displacement distributions. Biochim Biophys Acta (2005) 1.18
Endothelial-like cells expanded from CD34+ blood cells improve left ventricular function after experimental myocardial infarction. FASEB J (2005) 1.18
Diagnosis of hepatic metastasis: comparison of respiration-triggered diffusion-weighted echo-planar MRI and five t2-weighted turbo spin-echo sequences. AJR Am J Roentgenol (2008) 1.17
Soluble glycoprotein VI dimer inhibits platelet adhesion and aggregation to the injured vessel wall in vivo. FASEB J (2003) 1.16
Pattern-based differential diagnosis in pulmonary vasculitis using volumetric CT. AJR Am J Roentgenol (2005) 1.13
Ultrasmall supraparamagnetic iron oxide-enhanced magnetic resonance imaging of antigen-induced arthritis: a comparative study between SHU 555 C, ferumoxtran-10, and ferumoxytol. Invest Radiol (2006) 1.12
Expression of the interferon regulatory factor 8/ICSBP-1 in human reactive lymphoid tissues and B-cell lymphomas: a novel germinal center marker. Am J Surg Pathol (2008) 1.12
In vitro and in vivo spiral CT to determine bone mineral density: initial experience in patients at risk for osteoporosis. Radiology (2004) 1.11
Performance of whole-body integrated 18F-FDG PET/MR in comparison to PET/CT for evaluation of malignant bone lesions. J Nucl Med (2013) 1.11
Inter- and intraobserver variability of MR arthrography in the detection and classification of superior labral anterior posterior (SLAP) lesions: evaluation in 78 cases with arthroscopic correlation. Eur Radiol (2009) 1.11
Rapamycin attenuates vascular wall inflammation and progenitor cell promoters after angioplasty. FASEB J (2004) 1.10
Aurora kinase inhibition overcomes cetuximab resistance in squamous cell cancer of the head and neck. Oncotarget (2011) 1.10
Hepatic epithelioid hemangioendothelioma: findings at CT and MRI including preliminary observations at diffusion-weighted echo-planar imaging. Abdom Imaging (2011) 1.09
Labeling stem cells with ferumoxytol, an FDA-approved iron oxide nanoparticle. J Vis Exp (2011) 1.09
Labeling hESCs and hMSCs with iron oxide nanoparticles for non-invasive in vivo tracking with MR imaging. J Vis Exp (2008) 1.09
Phenotyping of tumor biology in patients by multimodality multiparametric imaging: relationship of microcirculation, alphavbeta3 expression, and glucose metabolism. J Nucl Med (2010) 1.07
MDM2 antagonist nutlin-3 displays antiproliferative and proapoptotic activity in mantle cell lymphoma. Clin Cancer Res (2009) 1.07
Significance of sagittal reformations in routine thoracic and abdominal multislice CT studies for detecting osteoporotic fractures and other spine abnormalities. Eur Radiol (2008) 1.05
Quantification of breast tumor microvascular permeability with feruglose-enhanced MR imaging: initial phase II multicenter trial. Radiology (2003) 1.05
Targeted dual-energy single-source CT for characterisation of urinary calculi: experimental and clinical experience. Eur Radiol (2011) 1.04
Bone structure of the distal radius and the calcaneus vs BMD of the spine and proximal femur in the prediction of osteoporotic spine fractures. Eur Radiol (2001) 1.04
Breast cancers: MR imaging of folate-receptor expression with the folate-specific nanoparticle P1133. Radiology (2010) 1.04
Does iterative reconstruction lower CT radiation dose: evaluation of 15,000 examinations. PLoS One (2013) 1.04
Optical imaging of cellular immunotherapy against prostate cancer. Mol Imaging (2009) 1.04
NPM-ALK-dependent expression of the transcription factor CCAAT/enhancer binding protein beta in ALK-positive anaplastic large cell lymphoma. Blood (2006) 1.03
Phase I trial of oral irinotecan and temozolomide for children with relapsed high-risk neuroblastoma: a new approach to neuroblastoma therapy consortium study. J Clin Oncol (2009) 1.03
Diagnostic performance of MR arthrography in the assessment of superior labral anteroposterior lesions of the shoulder. AJR Am J Roentgenol (2004) 1.03
MR signal characteristics of viable and apoptotic human mesenchymal stem cells in matrix-associated stem cell implants for treatment of osteoarthritis. Invest Radiol (2010) 1.02
Characterization of small (≤10 mm) focal liver lesions: value of respiratory-triggered echo-planar diffusion-weighted MR imaging. Eur J Radiol (2009) 1.02
Ferumoxytol: a new, clinically applicable label for stem-cell tracking in arthritic joints with MRI. Nanomedicine (Lond) (2013) 1.01
Predictive value of initial 18F-FLT uptake in patients with aggressive non-Hodgkin lymphoma receiving R-CHOP treatment. J Nucl Med (2011) 1.01
Detection, classification, and characterization of focal liver lesions: Value of diffusion-weighted MR imaging, gadoxetic acid-enhanced MR imaging and the combination of both methods. Abdom Imaging (2012) 1.00
The direct Myc target Pim3 cooperates with other Pim kinases in supporting viability of Myc-induced B-cell lymphomas. Oncotarget (2011) 1.00
Labeling human mesenchymal stem cells with fluorescent contrast agents: the biological impact. Mol Imaging Biol (2011) 1.00
Pulmonary embolism at multi-detector row CT of chest: one-year survival of treated and untreated patients. Radiology (2006) 0.99
PET/MR imaging in the detection and characterization of pulmonary lesions: technical and diagnostic evaluation in comparison to PET/CT. J Nucl Med (2014) 0.99
C/EBPβ expression in ALK-positive anaplastic large cell lymphomas is required for cell proliferation and is induced by the STAT3 signaling pathway. Haematologica (2009) 0.98
Synergistic antitumor effects of transarterial viroembolization for multifocal hepatocellular carcinoma in rats. Hepatology (2008) 0.98
MRI of the lung: value of different turbo spin-echo, single-shot turbo spin-echo, and 3D gradient-echo pulse sequences for the detection of pulmonary metastases. J Magn Reson Imaging (2007) 0.97
Variants of the superior labrum and labro-bicipital complex: a comparative study of shoulder specimens using MR arthrography, multi-slice CT arthrography and anatomical dissection. Eur Radiol (2005) 0.97
Trabecular bone structure of the distal radius, the calcaneus, and the spine: which site predicts fracture status of the spine best? Invest Radiol (2004) 0.97
Comparison of diffusion-weighted MR imaging and multidetector-row CT in the detection of liver metastases in patients operated for pancreatic cancer. Abdom Imaging (2011) 0.97
Magnetic resonance imaging of ferumoxide-labeled mesenchymal stem cells in cartilage defects: in vitro and in vivo investigations. Mol Imaging (2012) 0.97
Highly efficient paramagnetic labelling of embryonic and neuronal stem cells. Eur J Nucl Med Mol Imaging (2003) 0.96
Labeling human embryonic stem cell-derived cardiomyocytes with indocyanine green for noninvasive tracking with optical imaging: an FDA-compatible alternative to firefly luciferase. Cell Transplant (2010) 0.95
Comparison of cyclic RGD peptides for αvβ3 integrin detection in a rat model of myocardial infarction. EJNMMI Res (2013) 0.94
Different capacity of monocyte subsets to phagocytose iron-oxide nanoparticles. PLoS One (2011) 0.94
Neovascularization and angiogenic factors in advanced human carotid artery stenosis. Circ J (2012) 0.94
Adenocarcinomas of esophagogastric junction: multi-detector row CT to evaluate early response to neoadjuvant chemotherapy. Radiology (2006) 0.94
The epiphyseal torsion angle in MR arthrography of the hip: diagnostic utility in patients with femoroacetabular impingement syndrome. AJR Am J Roentgenol (2012) 0.94
Workflow and scan protocol considerations for integrated whole-body PET/MRI in oncology. J Nucl Med (2012) 0.93
Comparison of changes in tumor metabolic activity and tumor size during chemotherapy of adenocarcinomas of the esophagogastric junction. J Nucl Med (2005) 0.93
Iron-oxide-enhanced MR imaging of bone marrow in patients with non-Hodgkin's lymphoma: differentiation between tumor infiltration and hypercellular bone marrow. Eur Radiol (2002) 0.92
Automated CT volumetry of pulmonary metastases: the effect of a reduced growth threshold and target lesion number on the reliability of therapy response assessment using RECIST criteria. Eur Radiol (2007) 0.92
Molecular imaging of early αvβ3 integrin expression predicts long-term left-ventricle remodeling after myocardial infarction in rats. J Nucl Med (2012) 0.92
A phase I study of zoledronic acid and low-dose cyclophosphamide in recurrent/refractory neuroblastoma: a new approaches to neuroblastoma therapy (NANT) study. Pediatr Blood Cancer (2010) 0.92